Starling Oncology, Inc. Common Stock (STLN) Stock
NYSE · STLN
Key stats
- Market cap
- $428.36M
- Price / Earnings ratio
- -11.0x
- EPS (TTM)
- -$50304.74
- Volume
- Loading
- 52-week high
- $7.13
- 52-week low
- $2.32
Source: third-party data provider, as of November 13, 2026
Compare with STLN
Technical indicators
- RSI 14
- 33.46
- MACD 12/26/9
- -0.53
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.30
- SMA 50
- $6.32
- Price below SMA 50
- EMA 50
- $6.11
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold0
Buy3
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
603M398M199M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
314M207M104M0
Revenue to Profit
2025$502.7M
Revenue$0.0
Cost of revenue$76.4M
Gross profit$0.0
Operating expenses$-60.6M
Net incomeEarnings
No data available
Source: third-party data provider
About Starling Oncology, Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Care Facilities
Employees641
CEODr. Daniel Virnich FACHE, M.B.A., M.D.
IPO DateNov 15, 2021
HeadquartersCerritos, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Daniel Virnich FACHE, M.B.A., M.D. | CEO & Executive Director | 1979 |
| Mr. Robert Carter | Chief Financial Officer | 1986 |
| Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. | Chief Medical Officer | 1972 |
| Mr. Austin Lee | VP of Accounting & Controller | — |
| Mr. Rakesh Panda | Chief Information Officer | — |
| Ms. Minh Merchant | Chief Legal Officer | 1973 |
| Mr. Nolan Mariano | Chief People Officer | — |
| Mr. Mark Hueppelsheuser Esq. | General Counsel | — |
| Mr. Jordan McInerney | Chief Development Officer | — |
| Mr. Stephen Cella | Senior Vice President of Finance | — |
Fundamentals
Valuation
Price-to-sales ratio0.75
Price-to-book value-11.85
Profitability
Return on Equity236.00%
Return on Assets-24.00%
Return on Sales-6.00%
Gross margin (latest quarter)18.07%
EBITDA$-26.39M
Trading
Average volume2,923,732
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.46
- MACD 12/26/9
- -0.53
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.30
- SMA 50
- $6.32
- Price below SMA 50
- EMA 50
- $6.11
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $9.00
- Average
- $9.67
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +14.3 | +6.4 | +5.0 | -32.8 |
Compare stocks
Market cap
$428.36M
-
-
-
Price / Earnings ratio
-11.00
-
-
-
Price / Sales ratio
0.75
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
2,923,732
-
-
-
Earnings per share
$-50,304.74
-
-
-




